Business
Bionik Laboratories Corp. Issues Letter to Shareholders
Bionik Laboratories Corp. Issues Letter to Shareholders.
About this update from Bionik Laboratories Corp.
[{"type":"text","content":"\n\n\n\nBionik Laboratories Corp. Issues Letter to Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBionik Laboratories Corp. Issues Letter to Shareholders\nPR Newswire\nTORONTO and BOSTON, Aug. 22, 2017\n\n\n\nTORONTO and BOSTON, Aug. 22, 2017 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQB: BNKL) (\"Bionik\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today issued a letter to its shareholders. The letter can be read in full below:\n\nTo Our Valued Shareholders,\n\nI am pleased to provide you with an update of our progress over the last 12 months and to outline certain goals for the next year.\n\nThe first half of 2017 has been an important one for Bionik as we seek to strengthen our position as a company as we prepare to enter new markets. We are excited about the opportunities that lie ahead for our Company as we continue to execute on the advancement of our industry-leading product portfolio of assistive robotic technologies for the medical and home healthcare markets.\n\nThe Company has achieved several key milestones thus far in 2017 that we believe have also positioned us for increased growth:\n\n\nCompleted the development of the new V2 version of our InMotion robots, with improved design, footprint and user interface to enhance the user experience. We expect to begin delivery of these products this year.\nExpanded sales and marketing teams to lead business development and company awareness initiatives. This has resulted in a significantly expanded sales pipeline, which is expected to generate sales over the coming years.\nStrengthened position to enter growth markets in China through a joint venture partnership with Ginger Capital Investment to market and sell Bionik products into China, the largest single potential market for our products.\nSigned a co-development partnership with Wistron Corporation to co-develop and sell exoskeleton robots targeting the aging population. Wistron is a tier 1 Taiwan...